G Tsiropoulos1, T Papadas2, Ie Triantaphyllidou3, S Naxakis2, K Markou4, S Triaridis4, I Vital4, P Goumas2, Dh Vynios3. 1. Otolaryngology Department, AHEPA Hospital, Medical Faculty, Aristotle University of Thessaloniki, Thessaloniki, Greece ; Otolaryngology Department, University Hospital and School of Medical Sciences, University of Patras, Patras, Greece. 2. Otolaryngology Department, University Hospital and School of Medical Sciences, University of Patras, Patras, Greece. 3. Laboratory of Biochemistry, Department of Chemistry, University of Patras, Patras, Greece. 4. Otolaryngology Department, AHEPA Hospital, Medical Faculty, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Abstract
INTRODUCTION: Laryngeal cancer, especially in the advanced stages, is a highly devastating disease, characterized by increased invasiveness and high rates of metastasis. Gelatinases A and B (MMP-2 and -9 respectively) are of particular interest due to their contribution to various stages of carcinogenesis. There is a growing body of evidence with regard to the prognostic value of certain MMPs and their possible role as tumour markers. AIM: To identify the pattern of alteration of serum gelatinases A and B in patients with laryngeal cancer following treatment, and a possible correlation with various clinicopathological parameters. MATERIALS AND METHODS: Forty nine patients were included in this study. Pre-treatment and post-treatment serum samples were collected and processed by gelatin zymography and western blotting. RESULTS: Only the latent forms of MMP-2 and -9 were identified. Both gelatinases were increased in the serum of laryngeal cancer patients compared to healthy individuals. Patients with supraglottic tumours and active smokers had significantly higher pre-treatment levels of proMMP-2 than patients with glottic tumours (p < 0.05) and ex-smokers (p < 0.05), respectively. Patients with primary disease and patients with lymph node involvement showed lower serum proMMP-9 pre-treatment levels than patients with recurrence (p < 0.05) and patients without neck disease (p < 0.1), respectively. During the follow-up period the proMMP-2 serum levels increased significantly in the first ten to fifteen days after treatment, gradually decreasing over the following months. The proMMP-9 serum levels showed a gradual decrease after treatment, which was statistically significant (p<0.05). CONCLUSIONS: The post-treatment alteration pattern of proMMP-9 serum levels shows a possible role of this molecule as a tumour marker in laryngeal cancer. Further research is necessary to clarify the contribution of both gelatinases to the disease progress and determine their role as prognostic factors and tumour markers.
INTRODUCTION:Laryngeal cancer, especially in the advanced stages, is a highly devastating disease, characterized by increased invasiveness and high rates of metastasis. Gelatinases A and B (MMP-2 and -9 respectively) are of particular interest due to their contribution to various stages of carcinogenesis. There is a growing body of evidence with regard to the prognostic value of certain MMPs and their possible role as tumour markers. AIM: To identify the pattern of alteration of serum gelatinases A and B in patients with laryngeal cancer following treatment, and a possible correlation with various clinicopathological parameters. MATERIALS AND METHODS: Forty nine patients were included in this study. Pre-treatment and post-treatment serum samples were collected and processed by gelatin zymography and western blotting. RESULTS: Only the latent forms of MMP-2 and -9 were identified. Both gelatinases were increased in the serum of laryngeal cancerpatients compared to healthy individuals. Patients with supraglottic tumours and active smokers had significantly higher pre-treatment levels of proMMP-2 than patients with glottic tumours (p < 0.05) and ex-smokers (p < 0.05), respectively. Patients with primary disease and patients with lymph node involvement showed lower serum proMMP-9 pre-treatment levels than patients with recurrence (p < 0.05) and patients without neck disease (p < 0.1), respectively. During the follow-up period the proMMP-2 serum levels increased significantly in the first ten to fifteen days after treatment, gradually decreasing over the following months. The proMMP-9 serum levels showed a gradual decrease after treatment, which was statistically significant (p<0.05). CONCLUSIONS: The post-treatment alteration pattern of proMMP-9 serum levels shows a possible role of this molecule as a tumour marker in laryngeal cancer. Further research is necessary to clarify the contribution of both gelatinases to the disease progress and determine their role as prognostic factors and tumour markers.
Entities:
Keywords:
MMP-2; MMP-9; gelatinases; head and neck cancer; laryngeal cancer; matrix metalloproteinases; serum
Authors: A Torii; Y Kodera; K Uesaka; T Hirai; K Yasui; T Morimoto; Y Yamamura; T Kato; T Hayakawa; N Fujimoto; T Kito Journal: Br J Surg Date: 1997-01 Impact factor: 6.939
Authors: Stella M Ranuncolo; Elena Matos; Dora Loria; Marta Vilensky; Rodrigo Rojo; Elisa Bal de Kier Joffé; Lydia Inés Puricelli Journal: Cancer Date: 2002-03-01 Impact factor: 6.860
Authors: S Kurahara; M Shinohara; T Ikebe; S Nakamura; M Beppu; A Hiraki; H Takeuchi; K Shirasuna Journal: Head Neck Date: 1999-10 Impact factor: 3.147
Authors: Yuan-Chin Amy Lee; Paolo Boffetta; Erich M Sturgis; Qingyi Wei; Zuo-Feng Zhang; Joshua Muscat; Philip Lazarus; Elena Matos; Richard B Hayes; Deborah M Winn; David Zaridze; Victor Wünsch-Filho; Jose Eluf-Neto; Sergio Koifman; Dana Mates; Maria Paula Curado; Ana Menezes; Leticia Fernandez; Alexander W Daudt; Neonila Szeszenia-Dabrowska; Eleonora Fabianova; Peter Rudnai; Gilles Ferro; Julien Berthiller; Paul Brennan; Mia Hashibe Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-08 Impact factor: 4.254